Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Daniel Couch +33 (0)1 80 50 12 96
d-couch@unicancer.fr


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Back

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Biliary Tract Cancer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The object of this trial is to test whether ivonescimab is superior to standard chemotherapy (FOLFOX regimen) for the treatment of patients with advanced biliary tract cancer after failure of a first line of chemotherapy. It is only open to patients who participated in the SAFIR-ABC10 trial (NCT05615818) but did not receive experimental treatment.

Eligible patients will be randomised (2:1) to receive either ivonescimab or FOLFOX. Treatment will be continued until disease progression, or a maximum of 34 cycles of ivonescimab (experimental arm), whichever occurs first.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2025 Aug 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 20 mg/kg IV infusion every 3 weeks

Intervention Arm Group : Experimental;

Intervention Type : DRUG
Intervention Description : oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks

Intervention Arm Group : Control;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

Daniel Couch +33 (0)1 80 50 12 96
d-couch@unicancer.fr



The study is sponsored by UNICANCER and is in collaboration with Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; Summit Therapeutics.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06529718
Last updated 18 May 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top